Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
Toshinori HiraiR YamagaA FujitaT ItohPublished in: Journal of clinical pharmacy and therapeutics (2018)
This study demonstrated that BMI provides useful information for the identification of potential risk for hyperkalaemia associated with ACEI and ARB treatments.